Regeneron Pharmaceuticals
Update in progressREGN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines to treat diseases worldwide. Its therapies include EYLEA for various retinal diseases; Dupixent for atopic dermatitis and asthma; Libtayo for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent for heterozygous familial hypercholesterolemia; and Kevzara for rheumatoid arthritis. It partners with Bayer, Alnylam, Intellia, Hansoh, and Tessera. Founded 1988, based in Tarrytown, NY.
Company score
- Sentiment
- 0.02
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.48
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.41
- Governance
- -1.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Leonard S. Schleifer M.D., Ph.D.
- Founded1988
- Employees15,410
- Websitewww.regeneron.com
Identifiers
- ISINUS75886F1075
- FIGIBBG000C734W3
- LEI549300RCBFWIRX3HYQ56
- CUSIP75886F107
- CIK0000872589